Earnings Season Split: 52% of Companies Beat Estimates in Volatile Week

This week’s earnings season (March 23–27, 2026) delivered a tale of two markets, with results split almost down the middle. Out of 58 US-listed companies reporting quarterly results, 30 managed to beat analyst estimates—a 52% beat rate—while 28 fell short. The most dramatic stories came from the extremes: a cluster of biotech and tech firms stunned Wall Street by reporting smaller-than-expected losses, while others, particularly in consumer goods and finance, plunged by missing estimates by shocking margins. The data paints a picture of a market rewarding operational efficiency and punishing any sign of weakness.

The Week’s Biggest Winners

The top of the leaderboard this week is dominated by companies that turned in a surprising performance: reporting a loss of zero dollars against expectations of a significant deficit. This “less-bad-than-feared” narrative drove massive percentage surprises.

FAT Brands (FAT), a global franchising company, delivered the headline surprise. The company reported an actual EPS of $0.00, dramatically beating the consensus estimate of a $2.40 loss—a +100% surprise. While breaking even is not typically cause for celebration, in the context of heavy analyst pessimism, it signals potential stabilization. The company’s forward estimates suggest analysts see continued, albeit slow, improvement in its earnings trajectory.

89bio (ETNB), a clinical-stage biopharmaceutical company, followed a similar script. It reported a $0.00 EPS against an estimated loss of $0.52, also a +100% beat. For a biotech firm burning cash on drug development, coming in with no quarterly loss is a significant operational achievement that can extend its financial runway and boost investor confidence in its management’s cost controls.

Kodiak Sciences (KOD), another player in the biotech sector specializing in retinal diseases, rounded out the top three with its own +100% surprise ($0.00 actual vs. -$1.01 estimate). This trio of zero-loss reports from companies expected to post deep red ink suggests a sector-wide trend of aggressive cost management that is impressing the market more than top-line growth at this stage.

Beyond the perfect beats, other companies posted staggering improvements. Bionano Genomics (BNGO), a genomics instrumentation company, came within a hair of breaking even, posting a loss of just $0.03 against an expected $4.14 loss—a +99.28% surprise. This indicates a monumental shift in its financial profile. Meanwhile, Argan (AGX), a construction and engineering services firm, delivered a pure profit beat, earning $3.47 per share against a $1.98 estimate (+75.25%), showcasing strength in industrial and infrastructure projects.

The common thread among the winners is expectation reset. In a market wary of cash burn, companies that demonstrated severe cost discipline—even if still unprofitable—were rewarded handsomely. The market’s message is clear: controlling the bottom line is paramount.

Major Disappointments

On the other side of the ledger, the misses were severe, often involving companies that were expected to turn a profit but reported a loss, resulting in a -100% surprise. These weren’t minor stumbles; they were complete breakdowns versus expectations.

The week’s worst performer was ABVX (ABVX), a publicly traded company in the biopharma space. It reported a loss of $3.08 per share, a staggering -353% miss compared to the estimated loss of $0.68. This magnitude of miss suggests a fundamental disconnect between company guidance and analyst models, often triggering a crisis of confidence and a steep sell-off.

MultiPlan Corporation (MPLT), a healthcare cost management provider, delivered another deep disappointment. Its loss of $2.47 per share was nearly three times worse than the anticipated $0.83 loss, a -197.59% surprise. For a company in the steady healthcare sector, such a large miss points to potential operational challenges or unexpected costs that spook investors looking for predictability.

The list of -100% surprises reveals a painful pattern: companies forecasted for solid profits that delivered nothing. FinVolution Group (FINV), a fintech platform, was expected to earn $2.19 but reported $0.00. Guess? (GES), the apparel retailer, missed its $1.46 estimate with a $0.00 result. Viomi Technology (VIOT), a smart home company, and Baozun (BZUN), an e-commerce service provider, also fell from expected profits to zero. These results indicate sudden drops in demand, failed product launches, or unexpected expenses that completely wiped out projected earnings.

The defining characteristic of the major disappointments is a loss of predictability. When a company expected to earn over a dollar per share reports zero, it shatters the investment thesis and forces a brutal reassessment of its near-term prospects and management credibility. The market reaction to these misses is typically swift and severe.

Market Analysis & Key Takeaways

What do these results tell us about the market? The 52% beat rate indicates a fragile equilibrium. Analysts are not systematically too pessimistic or too optimistic, but company-specific execution is creating wild swings in stock performance.

The “Less Bad” Trade is Working: In a higher-interest-rate environment, investors are laser-focused on cash flow and burn rates. Companies like FAT, ETNB, and KOD, which reported smaller-than-feared losses, are being rewarded not for growth, but for survival and efficiency. This is a defensive market posture.

Zero-Tolerance for Profit Misses: The long list of -100% surprises (profit to zero) shows the market has no patience for companies that fail to meet baseline profitability expectations. This is especially true for consumer-facing names like Guess? and fintechs like FinVolution, where competition is fierce and margins are thin.

Biotech Dichotomy: The biotech sector was featured on both the winners and losers lists. The difference came down to expectations management. Companies that guided analysts accurately towards a “less bad” outcome won. Those where losses ballooned far beyond estimates were crushed. Volatility in this sector remains extreme.

International Headwinds: Several companies with significant international exposure, such as Baozun (China) and Viomi (China), featured among the major misses. This suggests persistent macroeconomic challenges or competitive pressures in key overseas markets are impacting bottom-line results more than analysts anticipated.

Analyst Estimates Need Scrutiny: The sheer magnitude of some beats and misses—like BNGO’s +99% or ABVX’s -353%—raises questions about the quality and timeliness of analyst models. In fast-moving or volatile industries, consensus estimates can become quickly outdated, creating outsized trading opportunities (and risks) around earnings.

Frequently Asked Questions

Why are companies reporting $0.00 EPS considered a “beat”?

It’s all about expectations. If analysts collectively estimate a company will lose $2.40 per share (like FAT Brands), and it instead reports a loss of $0.00, it has performed significantly better than feared. The “beat” is relative to the negative expectation. In a challenging market, avoiding a predicted cash burn is seen as a positive operational achievement that can boost investor confidence and extend the company’s financial runway, even if it isn’t yet profitable.

What should I do if a stock I own has a major earnings miss?

First, review the company’s explanation in its earnings release and conference call. Was the miss due to a one-time charge, a macroeconomic factor, or a deeper operational issue? Compare the stock’s reaction to the size of the miss. A -100% miss (profit to zero) often requires a fundamental reassessment of your investment thesis. It’s crucial to determine if the problem is temporary or indicative of a broken business model. Do not make impulsive decisions, but do not ignore a miss of this magnitude.

How reliable are analyst EPS estimates?

Analyst estimates represent a consensus forecast based on public information, company guidance, and industry trends. They are a useful benchmark but are not infallible. As seen this week, estimates can be wildly off, especially for volatile sectors like biotech or companies undergoing rapid change. Estimates are more reliable for stable, mature companies. Always treat them as educated guesses, not guarantees, and pay close attention to whether a company has a history of beating or missing estimates.

What does a 52% beat rate indicate for the overall market?

A beat rate just above 50% suggests a balanced but tense market. It indicates analysts, on average, have their models calibrated reasonably well, but there is no broad tailwind lifting all companies. Stock performance is becoming highly idiosyncratic, driven by individual company execution rather than sector-wide trends. This environment favors diligent stock-picking over passive index investing, as the gap between winners and losers is exceptionally wide.

Looking Ahead

The split market revealed this week sets the stage for increased volatility. Investors will be scrutinizing upcoming reports for signs of which trend prevails: the cost-control discipline of the winners or the profit-eroding challenges of the losers. Key sectors to watch next week include traditional retail and software, where margin pressure and competitive dynamics will be under the microscope. The primary market catalyst will be whether the “less bad is good enough” narrative continues to support stocks, or if investors begin demanding actual profit growth to justify valuations.

Disclaimer

This content is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The analysis is based on data believed to be reliable, but its accuracy cannot be guaranteed. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.